<DOC>
	<DOCNO>NCT00854581</DOCNO>
	<brief_summary>RATIONALE : Human T-cell lymphotropic virus type 1 cause cancer . Zidovudine antiviral drug act human T-cell lymphotropic virus type 1 . Giving zidovudine , interferon alfa-2b , PEG-interferon alfa-2b together may stimulate immune system slow keep cancer cell grow . PURPOSE : This clinical trial study well give zidovudine together interferon alfa-2b PEG-interferon alfa-2b work treat patient human T-cell lymphotropic virus type 1-associated adult T-cell leukemia/lymphoma .</brief_summary>
	<brief_title>Zidovudine , Interferon Alfa-2b , PEG-Interferon Alfa-2b Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To investigate whether lack IRF-4 and/or c-Rel associate response ( complete response partial response ) zidovudine , recombinant interferon alfa-2b , PEG-interferon alfa-2b therapy patient human T-cell lymphotropic virus type 1-associated adult T-cell leukemia/lymphoma ( ATLL ) . - To analyze , responder , presence remain detectable clone ATLL ( minimal residual disease ) 3 6 month maintain remission antiviral one-year post-initiation therapy order determine whether represent persistence original tumor clone another variant . - To analyze clone patient relapse determine whether antiviral escape associate expression IRF-4 , c-Rel , molecular event ( p53 , p16 mutation ) include expansion novel clone . - To investigate whether zidovudine function inhibitor NF-κB vivo analyze serially collect leukemic sample first 48 hour treatment zidovudine alone . - To determine effect valproic acid therapy persistent clonal disease patient complete stable partial remission . Secondary - To determine failure-free survival overall survival patient . OUTLINE : This multicenter study . - Induction therapy : Patients receive zidovudine IV twice daily day 1-14 , recombinant interferon alfa-2b IV twice daily day 3-14 . Patients achieve clinical complete response ( CR ) proceed part 1 maintenance therapy ; patient achieve partial response ( PR ) receive another 7 day zidovudine recombinant interferon alfa-2b proceed part 1 maintenance therapy . - Part 1 maintenance therapy : Patients receive oral zidovudine twice daily PEG-interferon alfa-2b subcutaneously ( SC ) weekly , begin day 14 21 continue day 60 . Patients evaluated completion part 1 maintenance therapy proceed part 2 maintenance therapy . - Part 2 maintenance therapy : Patients achieve CR undetectable clonal disease proceed group A ; patient achieve CR minimal residual disease ( PCR ) PR proceed group B . - Group A : Patients receive oral zidovudine twice daily PEG-interferon alfa-2b SC weekly . Treatment continue absence disease progression unacceptable toxicity . - Group B : Patients receive oral zidovudine twice daily PEG-interferon alfa-2b SC weekly 12 week undergo reevaluation . Patients continue CR minimal residual disease stable PR receive oral valproic acid twice daily , PEG-interferon alfa-2b SC weekly , oral zidovudine twice daily 6 month . At point ( month 9 ) patient detectable clonal disease continue previous treatment , patient minimal residual disease receive PEG-interferon alfa-2b SC oral zidovudine twice daily absence disease progression unacceptable toxicity . Blood sample collect baseline , day 1 2 , month 3 , 6 , 12 protein , genomic DNA , RNA analysis . Baseline molecular characteristic tumor tumor response treatment assess . After completion study treatment , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis adult Tcell leukemia/lymphoma Any stage disease Leukemic type ( smolder , chronic , acute ) Tumors must CD3 positive ( &gt; 50 % cell express CD3 ) Documented human Tcell lymphotropic virus type 1 ( HTLV1 ) infection serologic assay ( ELISA , western blot ) confirm HTLV1 rather HTLV2 differential western blot PCR Measurable evaluable disease PATIENT CHARACTERISTICS : Karnofsky performance status 50100 % ANC ≥ 1,500/mm^3 Platelet count ≥ 50,000/mm^3 unless cytopenia secondary adult Tcell leukemia/lymphoma Transaminases ≤ 7 time upper limit normal unless secondary hepatic infiltration lymphoma Total bilirubin &lt; 2.0 mg/dL unless secondary hepatic infiltration lymphoma ( secondary indinavir atazanavir therapy , patient eligible provided total bilirubin ≤ 3.5 mg/dL direct bilirubin normal ) Creatinine &lt; 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study treatment No grade 3 4 cardiac failure Ejection fraction ≥ 50 % No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement No concurrent active malignancy except situ carcinoma cervix ; nonmetastatic , nonmelanomatous skin cancer ; Kaposi 's sarcoma require systemic chemotherapy No autoimmune viral hepatitis decompensated liver disease unless due lymphoma No hypersensitivity recombinant interferon alfa2b , PEGinterferon alfa2b , zidovudine , component formulation No psychological , familial , sociological , geographical condition preclude study treatment and/or medical followup HIV positivity allow PRIOR CONCURRENT THERAPY : Patients already receive erythropoietin filgrastim ( GCSF ) allow Concurrent antiretroviral therapy HIVpositive patient allow No prior zidovudine and/or interferon No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>HTLV-1 infection</keyword>
</DOC>